Thyroid carcinoma, version 2.2014

Featured updates to the NCCN guidelines

R. Michael Tuttle*, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Andreas Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge & 10 others Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, Miranda Hughes

*Corresponding author for this work

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Original languageEnglish (US)
Pages (from-to)1671-1680
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Thyroid Neoplasms
Guidelines
Phosphotransferases
Iodine
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q. Y., ... Hughes, M. (2014). Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 12(12), 1671-1680. https://doi.org/10.6004/jnccn.2014.0169
Tuttle, R. Michael ; Haddad, Robert I. ; Ball, Douglas W. ; Byrd, David ; Dickson, Paxton ; Duh, Quan Yang ; Ehya, Hormoz ; Haymart, Megan ; Hoh, Carl ; Hunt, Jason P. ; Iagaru, Andrei ; Kandeel, Fouad ; Kopp, Peter Andreas ; Lamonica, Dominick M. ; Lydiatt, William M. ; McCaffrey, Judith ; Moley, Jeffrey F. ; Parks, Lee ; Raeburn, Christopher D. ; Ridge, John A. ; Ringel, Matthew D. ; Scheri, Randall P. ; Shah, Jatin P. ; Sherman, Steven I. ; Sturgeon, Cord ; Waguespack, Steven G. ; Wang, Thomas N. ; Wirth, Lori J. ; Hoffmann, Karin G. ; Hughes, Miranda. / Thyroid carcinoma, version 2.2014 : Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 12. pp. 1671-1680.
@article{d6b1c70b324a461b9f17714d234b5428,
title = "Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines",
abstract = "These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on {"}Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer{"} was added to the NCCN Guidelines to assist with using these novel targeted agents.",
author = "Tuttle, {R. Michael} and Haddad, {Robert I.} and Ball, {Douglas W.} and David Byrd and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Megan Haymart and Carl Hoh and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Kopp, {Peter Andreas} and Lamonica, {Dominick M.} and Lydiatt, {William M.} and Judith McCaffrey and Moley, {Jeffrey F.} and Lee Parks and Raeburn, {Christopher D.} and Ridge, {John A.} and Ringel, {Matthew D.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Sherman, {Steven I.} and Cord Sturgeon and Waguespack, {Steven G.} and Wang, {Thomas N.} and Wirth, {Lori J.} and Hoffmann, {Karin G.} and Miranda Hughes",
year = "2014",
month = "12",
day = "1",
doi = "10.6004/jnccn.2014.0169",
language = "English (US)",
volume = "12",
pages = "1671--1680",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "12",

}

Tuttle, RM, Haddad, RI, Ball, DW, Byrd, D, Dickson, P, Duh, QY, Ehya, H, Haymart, M, Hoh, C, Hunt, JP, Iagaru, A, Kandeel, F, Kopp, PA, Lamonica, DM, Lydiatt, WM, McCaffrey, J, Moley, JF, Parks, L, Raeburn, CD, Ridge, JA, Ringel, MD, Scheri, RP, Shah, JP, Sherman, SI, Sturgeon, C, Waguespack, SG, Wang, TN, Wirth, LJ, Hoffmann, KG & Hughes, M 2014, 'Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 12, pp. 1671-1680. https://doi.org/10.6004/jnccn.2014.0169

Thyroid carcinoma, version 2.2014 : Featured updates to the NCCN guidelines. / Tuttle, R. Michael; Haddad, Robert I.; Ball, Douglas W.; Byrd, David; Dickson, Paxton; Duh, Quan Yang; Ehya, Hormoz; Haymart, Megan; Hoh, Carl; Hunt, Jason P.; Iagaru, Andrei; Kandeel, Fouad; Kopp, Peter Andreas; Lamonica, Dominick M.; Lydiatt, William M.; McCaffrey, Judith; Moley, Jeffrey F.; Parks, Lee; Raeburn, Christopher D.; Ridge, John A.; Ringel, Matthew D.; Scheri, Randall P.; Shah, Jatin P.; Sherman, Steven I.; Sturgeon, Cord; Waguespack, Steven G.; Wang, Thomas N.; Wirth, Lori J.; Hoffmann, Karin G.; Hughes, Miranda.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 12, 01.12.2014, p. 1671-1680.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Thyroid carcinoma, version 2.2014

T2 - Featured updates to the NCCN guidelines

AU - Tuttle, R. Michael

AU - Haddad, Robert I.

AU - Ball, Douglas W.

AU - Byrd, David

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Haymart, Megan

AU - Hoh, Carl

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Kopp, Peter Andreas

AU - Lamonica, Dominick M.

AU - Lydiatt, William M.

AU - McCaffrey, Judith

AU - Moley, Jeffrey F.

AU - Parks, Lee

AU - Raeburn, Christopher D.

AU - Ridge, John A.

AU - Ringel, Matthew D.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Sherman, Steven I.

AU - Sturgeon, Cord

AU - Waguespack, Steven G.

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Hoffmann, Karin G.

AU - Hughes, Miranda

PY - 2014/12/1

Y1 - 2014/12/1

N2 - These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

AB - These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=84918790948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918790948&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0169

DO - 10.6004/jnccn.2014.0169

M3 - Article

VL - 12

SP - 1671

EP - 1680

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 12

ER -